JXR (01951) has made significant progress in increasing the number of in vitro fertilization (IVF) egg retrieval cycles in the first three quarters.

JXR (01951) announced that as of September 30, 2025, the company has made significant progress in increasing the number of in vitro fertilization (IVF) egg retrieval cycles. The company maintains a high level of confidence in the long-term development prospects of the industry and the future growth of the group. This confidence stems from the group's solid industry foundation, continuous favorable policies from the government towards the industry, and the company's ongoing efforts to improve clinical outcomes, optimize patient care, and enrich service offerings. In the third quarter of 2025, with a series of management and operational improvement measures, coupled with a positive trend during this period, the overall decline in IVF egg retrieval cycles by the group has slowed down. It decreased from -8.3% from the first half of 2024 to the first half of 2025, to -5.2% from the first three quarters of 2024 to the first three quarters of 2025. Specifically, the number of IVF egg retrieval cycles at the company's flagship hospital in Chengdu has shrunk from -6.1% in the first half of 2025 to -1.9% as of September 30, 2025. The improvement in IVF egg retrieval cycles at the Shenzhen hospital is slower than at the Chengdu hospital, because the Shenzhen hospital is preparing for a relocation plan by the end of 2025. In the US market, the implementation delay of the California Senate Bill SB729 (which requires commercial insurance to cover assisted reproduction) has led to a delay in IVF egg retrieval cycles, resulting in a decrease in the company's IVF cycles in line with expectations.